Yongsheng-KY's 'Cell Triple Arrows' as Growth Drivers, Plans to List in Late April
Yongsheng-KY is set to list in late April, driven by its 'cell triple arrows' strategy: cell new drugs, cell supply, and cell services. The company possesses a large-scale private and public umbilical cord blood cell bank and has obtained FDA approval for its umbilical cord blood new drug, REGENECYTE. Its long COVID treatment drug is currently in Phase 3 clinical trials with the FDA, and partnership discussions are underway. Private umbilical cord blood storage services account for 90% of its revenue, with the US market being the primary focus. Yongsheng-KY is also actively expanding into the US and Southeast Asian markets through innovative business models like the 'public bank guarantee service' in collaboration with insurers like Shin Kong Life.
📋 Article Processing Timeline
- 📰 Published: April 8, 2026 at 18:45
- 🔍 Collected: April 8, 2026 at 19:00 (15 min after Published)
- 🤖 AI Analyzed: April 15, 2026 at 17:35 (166h 35m after Collected)
Yongsheng held a media exchange meeting today, where Li Dong-yang stated that the 'cell triple arrows' – cell new drugs, cell supply, and cell services – are Yongsheng's important growth drivers and have entered the harvest period.
He pointed out that Yongsheng's main revenue sources include providing umbilical cord blood for medical institutions for transplantation, and providing private umbilical cord blood storage services, with its main sales targets being transplant patients and the general public. Yongsheng's operational core is its large-scale private and public umbilical cord blood cell bank, and it is the only cell therapy company in Taiwan to have obtained a US FDA umbilical cord blood new drug license (BLA).
Among Yongsheng's top 10 shareholders are Diamond BioFund, United BioPharma, Fubon Financial Holding Venture Capital, and Shin Kong Financial Holding Chairman Wu Tung-liang.
He noted that in 2025, 90% of Yongsheng's revenue contribution came from private umbilical cord blood storage services, with the US market accounting for about 75% and Taiwan about 25%. For this year, the main revenue contribution will still come from private storage services, with the US market remaining the primary focus.
In addition, Yongsheng's core product, the umbilical cord blood cell new drug REGENECYTE, has been approved by the US FDA for the treatment of various hematopoietic and immune system diseases. Li Dong-yang said that based on this drug license, Yongsheng is accelerating the horizontal expansion of indications; among them, the Phase 2 clinical trial for long COVID syndrome successfully unblinded at the end of 2024 and obtained the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation. In January this year, it further obtained FDA's "Expanded Access Program (EAP)" fee approval.
Li Dong-yang stated that the long COVID treatment drug is currently under FDA Phase 3 review, and partners have been approached, hoping to achieve licensing or co-development goals during the Phase 3 clinical trial process.
In terms of revenue momentum, Yongsheng has pioneered an innovative business model called "public bank guarantee service." Through cooperation with insurance companies such as Shin Kong Life (formerly Taishin Life), umbilical cord blood public bank matching services are included in medical coverage. The company is now actively entering niche markets in the US and Southeast Asia, where the population is tens of times larger than Taiwan's. (Editor: Chang Liang-chih) 1150408
He pointed out that Yongsheng's main revenue sources include providing umbilical cord blood for medical institutions for transplantation, and providing private umbilical cord blood storage services, with its main sales targets being transplant patients and the general public. Yongsheng's operational core is its large-scale private and public umbilical cord blood cell bank, and it is the only cell therapy company in Taiwan to have obtained a US FDA umbilical cord blood new drug license (BLA).
Among Yongsheng's top 10 shareholders are Diamond BioFund, United BioPharma, Fubon Financial Holding Venture Capital, and Shin Kong Financial Holding Chairman Wu Tung-liang.
He noted that in 2025, 90% of Yongsheng's revenue contribution came from private umbilical cord blood storage services, with the US market accounting for about 75% and Taiwan about 25%. For this year, the main revenue contribution will still come from private storage services, with the US market remaining the primary focus.
In addition, Yongsheng's core product, the umbilical cord blood cell new drug REGENECYTE, has been approved by the US FDA for the treatment of various hematopoietic and immune system diseases. Li Dong-yang said that based on this drug license, Yongsheng is accelerating the horizontal expansion of indications; among them, the Phase 2 clinical trial for long COVID syndrome successfully unblinded at the end of 2024 and obtained the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation. In January this year, it further obtained FDA's "Expanded Access Program (EAP)" fee approval.
Li Dong-yang stated that the long COVID treatment drug is currently under FDA Phase 3 review, and partners have been approached, hoping to achieve licensing or co-development goals during the Phase 3 clinical trial process.
In terms of revenue momentum, Yongsheng has pioneered an innovative business model called "public bank guarantee service." Through cooperation with insurance companies such as Shin Kong Life (formerly Taishin Life), umbilical cord blood public bank matching services are included in medical coverage. The company is now actively entering niche markets in the US and Southeast Asia, where the population is tens of times larger than Taiwan's. (Editor: Chang Liang-chih) 1150408
FAQ
What are Yongsheng-KY's main growth strategies?
Yongsheng-KY's main growth strategies are the 'cell triple arrows': cell new drugs, cell supply, and cell services. These are important growth drivers for the company and have already entered the harvest period.
What is the current status of Yongsheng-KY's umbilical cord blood new drug 'REGENECYTE'?
REGENECYTE has obtained FDA approval and is used for treating various hematopoietic and immune system diseases. Specifically, its long COVID treatment drug successfully unblinded Phase 2 clinical trials at the end of 2024, received FDA's Regenerative Medicine Advanced Therapy (RMAT) designation, and obtained fee approval for the 'Expanded Access Program (EAP)' in January this year. It is currently in Phase 3 clinical trials, and partnership discussions are ongoing.